​

RAPT Therapeutics (RAPT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

RAPT Stock Forecast

RAPT Therapeutics (RAPT) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $44.60, with a high of $72.00 and a low of $9.00. This represents a 48.17% increase from the last price of $30.10.

- $15 $30 $45 $60 $75 High: $72 Avg: $44.6 Low: $9 Last Closed Price: $30.1

RAPT Stock Rating

RAPT Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (69.23%), 4 Hold (30.77%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 4 9 Strong Sell Sell Hold Buy Strong Buy

RAPT Price Target Upside V Benchmarks

TypeNameUpside
StockRAPT Therapeutics48.17%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts357
Avg Price Target$59.00$44.60$32.43
Last Closing Price$30.10$30.10$30.10
Upside/Downside96.01%48.17%7.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25133--7
Sep, 25124--7
Aug, 25124--7
Jul, 25113-16
Jun, 25114-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025H.C. Wainwright$72.00$30.03139.76%139.20%
Oct 27, 2025Yatin SunejaGuggenheim$70.00$29.53137.05%132.56%
Oct 13, 2025Barclays$35.00$26.7930.65%16.28%
Sep 26, 2025Leerink Partners$37.00$23.5057.45%22.92%
Aug 12, 2025Eliana MerleUBS$9.00$9.47-4.96%-70.10%
Nov 12, 2024Thomas SmithLeerink Partners$2.00$1.7414.94%-93.36%
Nov 12, 2024Alex ThompsonStifel Nicolaus$2.00$1.7414.94%-93.36%
Jan 04, 2023Guggenheim$55.00$19.83177.36%82.72%
Jan 04, 2023Wells Fargo$48.00$19.50146.15%59.47%
Dec 08, 2022Edward TenthoffPiper Sandler$33.00$16.48100.24%9.63%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 27, 2025H.C. WainwrightBuyBuyhold
Oct 27, 2025GuggenheimNeutralBuyinitialise
Oct 21, 2025Wells FargoOverweightOverweighthold
Oct 13, 2025BarclaysEqual-WeightOverweightinitialise
Aug 12, 2025UBSNeutralNeutralhold
Aug 08, 2025Wells FargoOverweightOverweighthold
Nov 12, 2024Leerink PartnersMarket PerformMarket Performhold
Aug 11, 2024Wells FargoOverweightOverweighthold
May 14, 2024Wolfe ResearchPeer Performdowngrade
May 10, 2024BarclaysOverweightEqual-Weightdowngrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.19$-2.49$-2.52$-3.05$-3.19----
Avg Forecast$-2.19$-2.57$-2.56$-3.11$-2.13$-0.85$-1.07$-1.13$-1.29
High Forecast$-2.19$-2.57$-2.56$-3.04$-2.06$-0.57$-0.21$-1.13$-1.29
Low Forecast$-2.19$-2.57$-2.56$-3.17$-2.25$-1.27$-1.92$-1.13$-1.29
Surprise %--3.11%-1.56%-1.93%49.77%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.04M$3.81M$1.53M------
Avg Forecast$4.59M$3.89M$1.69M--$768.35K$10.19M$101.25M$83.70M
High Forecast$4.59M$3.89M$1.69M--$768.35K$10.19M$101.25M$83.70M
Low Forecast$4.59M$3.89M$1.69M--$768.35K$10.19M$101.25M$83.70M
Surprise %9.84%-1.86%-9.58%------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-52.89M$-68.21M$-81.88M$-116.80M$-129.87M----
Avg Forecast$-83.98M$-98.68M$-98.13M$-116.80M$-82.56M$-35.15M$-40.96M$-43.32M$-49.46M
High Forecast$-83.98M$-98.68M$-98.13M$-116.56M$-79.03M$-21.76M$-8.13M$-43.32M$-49.46M
Low Forecast$-83.98M$-98.68M$-98.13M$-121.56M$-86.09M$-48.54M$-73.80M$-43.32M$-49.46M
Surprise %-37.02%-30.88%-16.56%-57.30%----

RAPT Forecast FAQ

Is RAPT Therapeutics stock a buy?

RAPT Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that RAPT Therapeutics is a favorable investment for most analysts.

What is RAPT Therapeutics's price target?

RAPT Therapeutics's price target, set by 13 Wall Street analysts, averages $44.6 over the next 12 months. The price target range spans from $9 at the low end to $72 at the high end, suggesting a potential 48.17% change from the previous closing price of $30.1.

How does RAPT Therapeutics stock forecast compare to its benchmarks?

RAPT Therapeutics's stock forecast shows a 48.17% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for RAPT Therapeutics over the past three months?

  • October 2025: 14.29% Strong Buy, 42.86% Buy, 42.86% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 14.29% Strong Buy, 28.57% Buy, 57.14% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 14.29% Strong Buy, 28.57% Buy, 57.14% Hold, 0% Sell, 0% Strong Sell.

What is RAPT Therapeutics’s EPS forecast?

RAPT Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.85, marking a -73.35% decrease from the reported $-3.19 in 2024. Estimates for the following years are $-1.07 in 2026, $-1.13 in 2027, and $-1.29 in 2028.

What is RAPT Therapeutics’s revenue forecast?

RAPT Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $768.35K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10.19M, followed by $101.25M for 2027, and $83.7M for 2028.

What is RAPT Therapeutics’s net income forecast?

RAPT Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-35.151M, representing a -72.93% decrease from the reported $-130M in 2024. Projections indicate $-40.962M in 2026, $-43.322M in 2027, and $-49.456M in 2028.